Crescendo Biologics
6 known investors
Crescendo Biologics develops T cell enhancing therapeutics for immuno-oncology, based on its Humabody platform, with clinical candidates including the bispecific CB307 and immune cell engager CB699. Its pipeline targets cancers such as metastatic castration-resistant prostate cancer, and it partners with companies like Zai Lab on additional Humabody-derived treatments.
BiotechHealthtech
Investors Β· 6
Frequently asked questions
- What does Crescendo Biologics do?
- Crescendo Biologics develops T cell enhancing therapeutics for immuno-oncology, based on its Humabody platform, with clinical candidates including the bispecific CB307 and immune cell engager CB699. Its pipeline targets cancers such as metastatic castration-resistant prostate cancer, and it partners with companies like Zai Lab on additional Humabody-derived treatments.
- Who are Crescendo Biologics's investors?
- Crescendo Biologics's investors include Andera Partners, Astellas Venture Management LLC, EMBL Ventures, Future Planet Capital, Quan Capital, Sofinnova Partners.